Background: People with depression are usually managed in primary care and antidepressants are often the first-line treatment, but only one third of patients respond fully to a single antidepressant. This paper describes the protocol for a randomised controlled trial (MIR) to investigate the extent to which the addition of the antidepressant mirtazapine is effective in reducing the symptoms of depression compared with placebo in patients who are still depressed after they have been treated with a selective serotonin reuptake inhibitor (SSRI) or serotonin and noradrenaline reuptake inhibitor (SNRI) for at least 6 weeks in primary care.Methods/DesignMIR is a two-parallel group, multi-centre, pragmatic, placebo controlled, randomised trial with allocation at the level of the individual. Eligible participants are those who: are aged 18 years or older; are currently taking an SSRI/SNRI antidepressant (for at least 6 weeks at an adequate dose); score ≥14 on the Beck Depression Inventory (BDI-II); have adhered to their medication; and meet ICD-10 criteria for depression (assessed using the Clinical Interview Schedule-Revised version).Participants who give written, informed consent, will be randomised to receive either oral mirtazapine or matched placebo, starting at 15 mg daily for 2 weeks and increasing to 30 mg daily thereafter, for up to 12 months (to be taken in addition to their usual antidepressant). Participants, their GPs, and the research team will all be blind to the allocation. The primary outcome will be depression symptoms at 12 weeks post randomisation, measured as a continuous variable using the BDI-II.Secondary outcomes (measured at 12, 24 and 52 weeks) include: response (reduction in depressive symptoms (BDI-II score) of at least 50 % compared to baseline); remission of depression symptoms (BDI-II <10); change in anxiety symptoms; adverse effects; quality of life; adherence to antidepressant medication; health and social care use, time off work and cost-effectiveness. All outcomes will be analysed on an intention-to-treat basis.A qualitative study will explore patients' views and experiences of either taking two antidepressants, or an antidepressant and a placebo; and GPs' views on prescribing a second antidepressant in this patient group.DiscussionThe MIR trial will provide evidence on the clinical and cost-effectiveness of mirtazapine as an adjunct to SSRI/SNRI antidepressants for patients in primary care who have not responded to monotherapy.Trial registrationEudraCT Number: 2012-000090-23 (Registered January 2012); ISRCTN06653773 (Registered September 2012)
from #Medicine via ola Kala on Inoreader http://ift.tt/1SsWewq
via IFTTT
Αρχειοθήκη ιστολογίου
-
►
2023
(138)
- ► Φεβρουαρίου (74)
- ► Ιανουαρίου (64)
-
►
2022
(849)
- ► Δεκεμβρίου (61)
- ► Σεπτεμβρίου (74)
- ► Φεβρουαρίου (65)
-
►
2021
(2936)
- ► Δεκεμβρίου (59)
- ► Σεπτεμβρίου (180)
- ► Φεβρουαρίου (325)
-
►
2020
(1624)
- ► Δεκεμβρίου (293)
- ► Σεπτεμβρίου (234)
- ► Φεβρουαρίου (28)
-
►
2019
(13362)
- ► Δεκεμβρίου (19)
- ► Σεπτεμβρίου (54)
- ► Φεβρουαρίου (5586)
- ► Ιανουαρίου (5696)
-
►
2018
(66471)
- ► Δεκεμβρίου (5242)
- ► Σεπτεμβρίου (5478)
- ► Φεβρουαρίου (4835)
- ► Ιανουαρίου (5592)
-
►
2017
(44259)
- ► Δεκεμβρίου (5110)
- ► Σεπτεμβρίου (5105)
-
▼
2016
(7467)
- ► Δεκεμβρίου (514)
- ► Σεπτεμβρίου (1038)
-
▼
Φεβρουαρίου
(793)
-
▼
Φεβ 03
(50)
- Scattering chamber facility for double-differentia...
- On separation of exchange term from the coefficien...
- Vibratory Urticaria Associated with a Missense Var...
- Effect of Removal of Planned Parenthood from the T...
- Detection of Protein Glycosylation Using Tip-Enhan...
- Prenatal reflex DNA screening for Down's syndrome:...
- Oxidised palm oil and sucrose induced hyperglycemi...
- Preference and willingness to pay for traditional ...
- Correction to Detection of Tetrodotoxins in Puffer...
- Video Imaging and Spatiotemporal Maps to Analyze G...
- Ex vivo Live Imaging of Lung Metastasis and Their ...
- A Novel Murine Model of Arteriovenous Fistula Fail...
- Sclerostin serum levels in patients with systemic ...
- Glucose: not always the bad guy
- Preclinical animal models of multiple myeloma
- Pavlovic et al. MAF expression linked with bone re...
- Goff et al. Cancellous bone failure and its relati...
- Waning et al. Bone factors implicated in cancer-re...
- Li et al. ITGBL1 promotes metastasis of breast can...
- Hillam et al. Skull and leg bones experience wide ...
- Anticancer effects of clinically acceptable colchi...
- Anxiety and depression among adolescents with atte...
- New insulins and newer insulin regimens: a review ...
- Evaluation of abnormal liver function tests
- The usefulness of cardiopulmonary exercise testing...
- Video training with peer feedback in real-time con...
- Multidimensional Analysis of 16 Glucose Isomers by...
- Design, synthesis and biological evaluation of imi...
- Recognition and detection of 8-oxo-rG in RNA using...
- Synthesis and evaluation of thiophene-based guanyl...
- Fluorescence Lifetime Imaging of Nanoflares for mR...
- Orientational Imaging of a Single Gold Nanorod at ...
- Identifying Pigment Mixtures in Art Using SERS: A ...
- Role of patient and tumor characteristics in senti...
- Ratios of central venous-to-arterial carbon dioxid...
- Changing the default to promote influenza vaccinat...
- Place of influenza vaccination among children—Unit...
- Successful introduction of an underutilized elderl...
- Erratum de l’article : « La pneumocystose chez le ...
- Atteinte respiratoire précoce chez les nourrissons...
- Colchicum autumnale in Patients with Goitre with E...
- Mirtazapine added to selective serotonin reuptake ...
- Minerals, Vol. 6, Pages 10: Biomineralization Patt...
- Diagnostic Value of Magnetic Resonance Spectroscop...
- KTP vs CO2 Laser for the Treatment of Laryngeal Ca...
- Interest of Navigation for the Treatment of Pertro...
- The Evaluation of Pre-Post Smoke Evacuation Uses o...
- Study of the Combination of BKM120 and Cisplatin o...
- Genotypic, physiological, and biochemical characte...
- Contribution of Blastocystishominis subtypes and a...
-
▼
Φεβ 03
(50)
Αναζήτηση αυτού του ιστολογίου
Τετάρτη 3 Φεβρουαρίου 2016
Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Αλέξανδρος Γ. Σφακιανάκης Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,0030693260717...
-
heory of COVID-19 pathogenesis Publication date: November 2020Source: Medical Hypotheses, Volume 144Author(s): Yuichiro J. Suzuki ScienceD...
-
Alimentary Pharmacology &Therapeutics, EarlyView. https://ift.tt/2qECBIJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.